Please note: The Federal Employees Health Benefits (FEHB) Program is not a federal or state government healthcare program for purposes of the savings program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Sanofi US Copay Program: This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. Upon registration, patients will receive all program details. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. There are other relevant costs associated with overall treatment. The Insulins Val you Savings Program applies to the cost of medication. When using the Insulins Val you Savings Card, prices are guaranteed for 12 consecutive monthly fills. Not valid for SOLIQUA 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL. To pay $35 per 30 Day Supply, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. For the duration of the program, eligible patients will pay $35 per 30 Day Supply. Only people without prescription medication insurance can apply for this offer. This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs, or commercial/private insurance. Insulins Val you Savings Program: Sanofi insulins included in this program are: ADMELOG ® (insulin lispro injection) 100 Units/mL, TOUJEO ® SoloStar ® (insulin glargine injection) 300 Units/mL, TOUJEO ® Max SoloStar ® (insulin glargine injection) 300 Units/mL, LANTUS ® (insulin glargine injection) 100 Units/mL, INSULIN GLARGINE injection 100 Units/mL (U-100) and APIDRA ® (insulin glulisine injection) 100 Units/mL. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered. These patients should be observed for signs and symptoms of heart failure. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.įluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Discontinue Lantus, treat and monitor until symptoms resolve.Ī reduction in the Lantus dose may be required in patients with renal or hepatic impairment.Īs with all insulins, Lantus use can lead to life-threatening hypokalemia. Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Patients should be instructed to always verify the insulin label before each injection. Hypoglycemia due to medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus, and may be life-threatening. Do not administer Lantus via an insulin pump or intravenously because severe hypoglycemia can occur. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.ĭo not dilute or mix Lantus with any other insulin or solution. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant drugs. Modify insulin regimen only under medical supervision. Monitor blood glucose in all patients treated with insulin. The program is for commercially insured patients only.Insulin pens, needles, or syringes must never be shared between patients. How much can I save?Your co-pay can be reduced to as little as $25 per prescription, with a maximum savings of $100 per month.ĭo I need insurance?Yes. How do I get the discount?Download and print from the program website. When you’re ready to use this coupon, simply present the coupon to your pharmacist with a valid prescription for your medication. These programs are free but may have some rules or restrictions, so you’ll want to review carefully. Many manufacturers offer programs that will reduce your out-of-pocket costs for this prescription.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |